Exendin agonist formulations and methods of administration...

Details Exendin agonist formulations and methods of administration... Exendin agonist formulations and methods of administration...

2005-06-07

2005-06-07

Carlson, Karen Cochrane (Department: 1653)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C424S278100, C514S002600, C514S003100, C514S004300, C514S012200, C514S866000, C530S300000

Reexamination Certificate

active

06902744

ABSTRACT:
Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.

REFERENCES:
patent: 5424286 (1995-06-01), Eng
patent: 6506724 (2003-01-01), Hiles et al.
patent: 6528486 (2003-03-01), Larsen et al.
patent: 2003/0087821 (2003-05-01), Beeley et al.
patent: WO 97/46584 (1997-12-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO 9830231 (1998-07-01), None
patent: WO 99/07404 (1999-02-01), None
patent: WO 99/25727 (1999-05-01), None
patent: WO 99/25728 (1999-05-01), None
patent: WO 99/40788 (1999-08-01), None
patent: WO 99/43708 (1999-09-01), None
Amylin Pharmaceuticals, Inc., Form 10-K Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, Mar. 15, 2002, pp. 1-8.
Baggio et al., “Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, β-Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic Mice,”J. Biol. Chem.275(44):34471-7 (2000).
Edwards et al., “Exendin-4 Reduces Fasting and Postprandial Glucose and Decreases Energy Intake in Healthy Volunteers,”Am. J. Physiol. Endocrinol. Metab.281:E155-61 (2001).
Egan et al., “The Insulinotropic Effect of Acute Exendin-4 Administered to Humans: Comparison of Nondiabetic State to Type 2 Diabetes,”J. Clin. Endocrinol.&Metab.87(3):1282-90 (2002).
Goke et al., “Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β-Cells,”J. Biol. Chem.268(26):19650-55 (1993) (previously submitted on Aug. 20, 2002).
International Search Report, International Application No. PCT/US03/16699 (Aug. 2003).
Tourrel et al., “Persistent Improvement of Type 2 Diabetes in the Goto-Kakizaki Rat Model by Expansion of the β-Cell Mass During the Prediabetic Period with Glucagon-Like Peptide-1 or Exendin-4,”Diabetes51:1443-52 (2002).
Bhavsar et al., “Inhibition of Gastric Emptying and of Food Intake Appear to be Independently Controlled in Rodents,” 25thAnnual Meeting, Nov. 11-16, 1995, San Diego, California,Soc. Neurosci., 21:460 (Abstract) (188.8).
D'Alessio et al., “Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons,”J. Clin. Invest., 97(1):133-38 (1996).
Daniel et al., “Use of Glucagon in the Treatment of Acute Diverticultis,”British Medical Journal, 3:720-2 (1974).
Eissele et al., “Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide,”Life Sci., 55(8):629-34 (1994).
Eng, “Prolonged Effect of Exendin-4 on Hyperglycemia of db/db Mice,”Diabetes, 45(Supp 2):152A (abstract 554) (1996).
Eng et al., “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated fromHeloderma horridumVenom,”J. Biol. Chem., 265(33):20259-62 (1990).
Eng et al., “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, fromHeloderma suspectumVenom,”J. Biol. Chem., 267(11):7402-5 (1992).
Glauser et al.,“Intravenous Glucagon in the Management of Esophageal Food Obstruction,”J. Am. Coll. Emer.(JACEP), 8(6):228-231 (1979).
Goke et al., “Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β-Cells,”J. Biol. Chem., 268(26):19650-55 (1993).
Kolligs et al., “Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin(9-39) Amide,”Diabetes, 44:16-19 (1995).
Montrose-Rafizadeh et al., Structure-function Analysis of Exendin-4 /.
O'Halloran et al., “Glucagon-like Peptide-1 (7-36)-NH2: a Physiological Inhibitor of Gastric Acid Secretion in Man,”J. Endocrinol., 126(1):169-73 (1990).
Ørskov et al., “Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable,”Diabetes, 42:658-61 (1993).
Raufman et al., “Exendin-3, a Novel Peptide fromHeloderma horridumVenom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newly Described Receptor on Dispersed Acini from Guinea Pig Pancreas,”J. Biol. Chem., 266(5):2897-902 (1991).
Raufman et al., “Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas”,J. Biol. Chem.267(30):21432-37 (1992).
Schepp et al., “Exendin-4 and Exendin-(9-39)NH2: Agonist and Antagonist, Respectively, at the Rat Parietal Cell Receptor for Glucagon-like Peptide-1-(7-36)NH2,”Eur. J. Pharm., 269:183-91 (1994).
Schjoldager et al., “GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans,”Digest. Dis. Sci., 34(5):703-8 (1989).
Stower et al., “A Trial of Glucagon in the Treatment of Painful Biliary Tract Disease,”Brit. J. Surg., 69:591-2 (1982).
Thorens et al., “Cloning and Functional Expression of the Human Islet GLP-1 Receptor,”Diabetes, 42(11):1678-82 (1993).
Thorens, “Expression Cloning of the Pancreatic β Cell Receptor for the Gluco-incretin Hormone Glucagon-like Peptide 1,”P. Natl. Acad. Sci. USA, 89:8641-45 (1992).
Turton et al., “A Role for Glucagon-like Peptide-1 in the Central Regulation of Feeding,”Nature, 379(6560):69-72 (1996).
Wang et al., “Glucagon-like Peptide-1 Is a Physiological Incretin in Rat,”J. Clin. Invest., 95:417-21 (1995).
Wettergren et al., “Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man,”Digest. Dis. Sci., 38(4):665-73 (1993).
Willms et al., “Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients,”J. Clin. Endocrinol. Metab., 81(1):327-32 (1996).

Affiliated with

Also associated with

Rating

Exendin agonist formulations and methods of administration... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Exendin agonist formulations and methods of administration..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Exendin agonist formulations and methods of administration... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3472141